Skip to main content
Premium Trial:

Request an Annual Quote

Slower than Breakneck

Premium

I was in college when the first draft of the human genome came out. Not long after, Craig Venter came to my university to speak at convocation about the Human Genome Project — the biology department was quite excited and many of us biology majors went, despite usually skipping convocation to do almost anything else. The title of Venter's talk was "Sequencing the Human Genome: Gateway to a New Era in Science and Medicine." At the 10th anniversary of the draft genome last year, some of that ebullience was glaringly absent. Critics were quick to say the $2.7 billion Human Genome Project hadn't made good on its promise to cure disease.

However, even if it isn't happening at breakneck speed, genomics does seem to be leading to changes in medicine and healthcare. In this month's cover story, Christie Rizk examines how genomics findings are moving into the clinic to tailor medical treatments to patients' needs. While it is slow going due to a number of challenges — not the least of which are teaching physicians about genomics, organizing genomics data for clinicians, and convincing insurance companies to pay for tests and drugs — personalized medicine is increasingly part of healthcare. The classic example, the Institute for Systems Biology's Lee Hood tells Christie, is Herceptin, which is not a one-size-fits-all drug as it treats HER2-positive breast cancer.

Elsewhere in this issue, Genome Technology presents the results of its biennial core lab survey. Both core lab and non-core lab scientists gave their feedback on the work cores are doing. Generally speaking, users are happy with their cores, though they'd like more sequencing tools and better bioinformatics. For their part, core lab workers would like to expand the number of tools they offer and have more automation. Head over to page 21 for the lowdown.

Finally, Matthew Dublin spoke with the University of British Columbia's Rosie Redfield for this month's Q&A. She has been making waves for the past year for her vocal criticism of a Science paper from NASA's Felisa Wolfe-Simon on a bacterium that could incorporate arsenic into its DNA instead of phosphate. Matt speaks with Redfield about her experiments to rebut those findings and the need for open science.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.